Avancées recentes dans le traitement des carcinomes corticosurrénaliens [Recent advances in the treatment of adrenocortical carcinomas].


Autoria(s): Ducry J.; Berthold D.; Pralong F.
Data(s)

2012

Resumo

Adrenocortical carcinomas are rare and aggressive malignant tumors, with an incidence of 1 to 2 cases per million inhabitants. Their diagnosis is made in three clinical situations: during the work up of a syndrome of hormonal hypersecretion, during the work up of locoregional symptoms, or incidentally during an unrelated radiological procedure. Surgery is usually indicated except in situations of advanced metastatic disease. Adjuvant chemotherapy with mitotane is associated with a significant increase in disease-free survival when the drug is administered at adequate therapeutic dosage. Novel anti-mitotic therapies have recently been described for treating recurrent adrenocortical carcinoma under mitotane treatment, but their overall efficacy remains unsatisfactory.

Identificador

http://serval.unil.ch/?id=serval:BIB_29943BAF3051

isbn:1660-9379 (Print)

pmid:23240320

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 8, no. 362, pp. 2181-4, 2186

Palavras-Chave #Adrenal Cortex Neoplasms/diagnosis; Adrenal Cortex Neoplasms/pathology; Adrenocortical Carcinoma/diagnosis; Adrenocortical Carcinoma/pathology; Antimitotic Agents/therapeutic use; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/therapeutic use; Chemotherapy, Adjuvant/methods; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Incidence; Neoplasm Recurrence, Local
Tipo

info:eu-repo/semantics/article

article